Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib

BACKGROUND: BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors b...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Queirolo, Paola, Spagnolo, Francesco, Picasso, Virginia, Spano, Laura, Tanda, Enrica, Fontana, Valeria, Giorello, Laura, Merlo, Domenico Franco, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Del Vecchio, Michele, Bruzzi, Paolo, Ascierto, Paolo Antonio
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Clinical Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5844757/
https://ncbi.nlm.nih.gov/pubmed/29552321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10589
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items